期刊文献+

叶酰多聚谷氨酸合成酶与甲氨蝶呤敏感性的关系 被引量:2

Relationship between folypolyglutamate synthetase and methotrexate drug sensitivity
原文传递
导出
摘要 叶酰多聚谷氨酸合成酶(folypolyglutamatesynthetase,FPGS)作为甲氨蝶呤(methotrexate,MTX)类抗肿瘤药物细胞内代谢过程中的关键酶,催化形成活性形式的MTX多聚谷氨酸,其异常是MTX耐药的重要原因之一。近年来研究发现,FPGS表达及活性的降低可使细胞内MTX多聚谷氨酸浓度降低,从而导致MTX耐药。FPGS基因多态性在MTX耐药中也起着重要的作用,但其具体机制尚未完全明了。该文就FPGS酶活性及基因多态性与MTX药物敏感性的关系进行综述。 Folypolyglutamate synthetase(FPGS) catalyzes the addition of multiple glutamate molecules to compounds with the basic pteroylglutamate structure, such as polyglutamylation-dependent novel antifolates. As the antifolates like methotrexate require polyglutamation by FPGS for activation, FPGS has an established position in the cytotoxic action of methotrexate and has become a essential part in methotrexate resistance. Recent studies have indicated that decreased mRNA expression and activity of FPGS can cause reduction of methotrex- ate-polyglutamates accumulation,which have been observed as a dominant mechanism leading to methotrexate resistance. Furthermore, single nucleotide polymorphism in FPGS has been displayed significant associations with methotrexate sensitivity and susceptibility of deseases, though the detail mechanism is unknown. This paper is to review the relationshitip among FPGS enzvme activitv. gene polvmorohism and methotrexate drug sensitivity.
出处 《国际儿科学杂志》 2012年第2期183-186,共4页 International Journal of Pediatrics
基金 国家自然科学基金资助项目(30471830) 深圳市科技计划项目(200802065)
  • 相关文献

参考文献24

  • 1Leclerc G, Mou C, Leclcrc G, et al. Histone deacetylase inhibitors induce FPGS mRNA expression and intracelhilar accumulation of long-chain methotrexate polyglutamates in childhood acute lympho- blastic leukemia: implications for combination therapy. Leukemia, 2010,24(3) :552-562.
  • 2Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity pro- file of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol,2009,64 (5) :993-999.
  • 3Gangjee A,Jain HD, Kurup S. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents. Anticancer Agents Med Chem,2007,7 (5) :514-542.
  • 4Odin E, Wettergren Y, Nilsson S, et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res, 2003,9 (16):6012- 6019.
  • 5Manritz R, Peters G, Priest D, et al. Multiple mechanisms of resist- ance to methotrexate and novel ntifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Plaarmaco1,2002,63(2 ) : 105-115.
  • 6Schneider E,Ryan TJ. Gamrna-glutamyl hydrolase and drug resistance. Clin Chim Acta,2006,374(1-2) :25-32.
  • 7Panetta JC, Yanishevski Y, Pui CH, et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmaco1,2002,50 ( 5 ) :419 -428.
  • 8Leclerc GJ,Barredo JC. Folylpoly-gamma-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues. Clin Cancer Res,2001,7(4) :942-951.
  • 9Leclerc G,Leclerc G,Kinser TTH,et al. Analysis of folylpoly-γ-glu- tamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells. BMC Cancer,2006,6 ( 132 ) : 132.
  • 10MeGuire JJ,Russell CA,Balinska M. Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophorefically distinct. J Biol Chem,2000,275(17) :13012-13016.

同被引文献24

  • 1梁运轩,覃月秋.HMGB1与细胞自噬、凋亡关系的研究进展[J].世界最新医学信息文摘,2020(8):51-52. 被引量:1
  • 2Huffman DH, Wan SH, Azarnoff DL, et al. Pharmacoki- netics of methotrexate [J]. Clinical Pharmacology and Ther- apeutics, 1973,14(4) :572-579.
  • 3Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate [J]. Biochemical and Biophys- ical Research Communications, 1973,52 ( 1 ) : 27-34.
  • 4Chabner BA, Allegra C J, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? [J]. Journal of Clinical Investigation, 1985,76 (3) : 907.
  • 5Willner N, Storch S, Tadmor T, et al. Almost a tragedy: se- vere methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy [J]. European Journal of Clinical Phar- macology, 2014,70 ( 3 ) : 261-263.
  • 6Frandsen TL, Abrahamsson J, Lausen B, et al. Individu- alized toxicity-titrated 6-mercaptopurine increments dur- ing high-dose methotrexate consolidation treatment of low- er risk childhood acute lymphoblastic leukaemia [J]. Br J Haematol, 2011,155 (2) : 244-247.
  • 7Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis [J]. J Rheumatol,2014, 41 (6) : 1049-1060.
  • 8Stamp LK, O'Donnell JL, Chapman PT, et al. Determi- nants of red blood cell methotrexate polyglutamate concen- trations in rheumatoid arthritis patients receiving long - term methotrexate treatment [J]. Arthritis & Rheumatism,2009,60 (8) : 2248-2256.
  • 9den Boer E, de Rotte MC, Pluijm SM, et al. Determinants of erythrocyte methotrexate polyglutamate levels in rheuma- toid arthritis [J]. The Journal of Rheumatology,2014,41 (11 ) : 2167-2178.
  • 10Suyagh MF, Iheagwaram G, Kole PL, et al. Development and validation of a dried blood spot-HPLC assay for the determination of metronidazole in neonatal whole blood samples [J]. Anal Bioanal Chem,2010,397(2):687-693.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部